Skip to content

Evaluation of the medium to long term impact of commercial open-group behavioural weight loss programmes on body weight and diabetes risk in adults with overweight and obesity: 5 & 10 year follow up of the WRAP trial

Evaluation of the medium to long term impact of commercial open-group behavioural weight loss programmes on body weight and diabetes risk in adults with overweight and obesity: 5 & 10 year follow up of the WRAP trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN64986150
Enrollment
1040
Registered
2018-02-01
Start date
2018-01-22
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, diabetes Nutritional, Metabolic, Endocrine

Interventions

The interventions used in the original WRAP trial (ISRCTN82857232) included: brief intervention (brief advice and self-help materials
BI), referral to a commercial open-group behavioural programme (Weight Watchers) for 12 weeks (CP12), and referral to the same programme for 52 weeks (CP52). Participant details were entered into the

Sponsors

University of Cambridge
Lead Sponsor
Cambridgeshire and Peterborough NHS Foundation Trust
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Participants who took part in the original WRAP study and consented for further follow up

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

MeasureTime frame
5 year (and 10 year) changes in weight, adjusted for baseline. Participants will be weighed at their local GP surgery using calibrated scales. Where participants are unable/unwilling to attend a visit the trialists will obtain a weight measurement from NHS records and/or self-report.

Secondary

MeasureTime frame
5 year changes (and 10 year changes) in: 1. Fat mass, measured by Tanita body composition analyser 2. HbA1C and lipid profile, measured by blood sample and analysed used standardised methods 3. Blood pressure, measured using OMRON meter in a resting state 4. Diabetes status (normoglycaemia, non-diabetic hyperglycaemia and diabetes) 5. Modelled 10-year cardiovascular risk (Q-Risk)

Countries

England, United Kingdom

Contacts

Public ContactJenny Woolston
Jenny.Woolston@mrc-epid.cam.ac.uk+44 (0)1223 769204

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 16, 2026